daratumumab
AssetAlso called 3003-005, HuMax-CD38, Darzalex
Anti-CD38 monoclonal antibody inducing targeted immune-mediated lysis of CD38-expressing cells.
- Stage
- Approved
- Modality
- Antibody
- Target
- CD38
- 16
- Indications
- 290
- Trials
- 1
- Developer
Approved by the FDA on Nov 16, 2015 (BLA761036). 2 approvals stand. FDA
Indications
16Multiple myeloma
Approved, FDA
Newly diagnosed multiple myeloma
Approved, EMA
Relapsed and refractory multiple myeloma
Approved, EMA
13 more
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials290
- Evidence for its targets2
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.